Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials

BACKGROUND: Chronic myeloid leukemia is successfully managed by imatinib therapy, but the question remains whether treatment must be administered indefinitely. Imatinib discontinuation trials have led to two distinct outcomes: about 60% of patients experienced disease relapse within 6 months of trea...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Tang, Min, Foo, Jasmine, Gönen, Mithat, Guilhot, Joëlle, Mahon, François-Xavier, Michor, Franziska
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2012
Assuntos:
Original Articles and Brief Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3487556/
https://ncbi.nlm.nih.gov/pubmed/22419579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.062844
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados